Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA A Cancer J Clin. 2009;59:225–49.

Article  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA A Cancer J Clin. 2023;73:17–48.

Article  Google Scholar 

Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharm Ther. 2013;140:223–38.

Article  CAS  Google Scholar 

Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev. 2014;33:399–411.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001.

Article  PubMed  PubMed Central  Google Scholar 

Burd CJ, Morey LM, Knudsen KE. Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer. 2006;13:979–94.

Article  CAS  PubMed  Google Scholar 

Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol. 2013;40:244–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lytton B. Prostate cancer: a brief history and the discovery of hormonal ablation treatment. J Urol. 2001;165:1859–62.

Article  CAS  PubMed  Google Scholar 

Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:4792–8.

Article  CAS  Google Scholar 

Sowery RD, So AI, Gleave ME. Therapeutic options in advanced prostate cancer: present and future. Curr Urol Rep. 2007;8:53–59.

Article  PubMed  Google Scholar 

Omlin A, de Bono JS. Therapeutic options for advanced prostate cancer: 2011 update. Curr Urol Rep. 2012;13:170–8.

Article  PubMed  Google Scholar 

Jacob A, Raj R, Allison DB, Myint ZW. Androgen receptor signaling in prostate cancer and therapeutic strategies. Cancers. 2021;13:5417.

Reiss AB, Saeedullah U, Grossfeld DJ, Glass AD, Pinkhasov A, Katz AE. Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function. Clin Transl Oncol. 2022;24:733–41.

Article  CAS  PubMed  Google Scholar 

Achard V, Putora PM, Omlin A, Zilli T, Fischer S. Metastatic prostate cancer: treatment options. Oncology. 2022;100:48–59.

Article  CAS  PubMed  Google Scholar 

Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol. 2010;7:197–208.

Article  PubMed  Google Scholar 

Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:1168–76.

Article  CAS  Google Scholar 

Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7:340–7.

Article  CAS  PubMed  Google Scholar 

Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Investig. 2008;26:1–10.

Article  CAS  Google Scholar 

Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. 2017;3:1663–72.

Article  PubMed  PubMed Central  Google Scholar 

Schiewer MJ, Knudsen KE. Linking DNA damage and hormone signaling pathways in cancer. Trends Endocrinol Metab. 2016;27:216–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009;138:245–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anantharaman A, Friedlander TW. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: a review. Urol Oncol. 2016;34:356–67.

Article  CAS  PubMed  Google Scholar 

Jadhavar PS, Ramachandran SA, Riquelme E, Gupta A, Quinn KP, Shivakumar D, et al. Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors. Bioorg Med Chem Lett. 2016;26:5222–8.

Article  CAS  PubMed  Google Scholar 

Li D, Zhou W, Pang J, Tang Q, Zhong B, Shen C, et al. A magic drug target: androgen receptor. Med Res Rev. 2019;39:1485–514.

Article  CAS  PubMed  Google Scholar 

Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, et al. Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19. JAMA Netw Open. 2021;4:e2134330.

Article  PubMed  PubMed Central  Google Scholar 

Shah H, Vaishampayan U. Therapy of advanced prostate cancer: targeting the androgen receptor axis in earlier lines of treatment. Target Oncol. 2018;13:679–89.

Article  PubMed  PubMed Central  Google Scholar 

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474–489.e476.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer. 2016;23:T179–T197.

Article  CAS  PubMed  Google Scholar 

Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, et al. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). Cancer. 2018;124:1216–24.

Article  CAS  PubMed  Google Scholar 

Schweizer MT, Yu EY. Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol. 2015;8:128.

Article  PubMed  PubMed Central  Google Scholar 

Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waddell AR, Huang H, Liao D CBP/p300: Critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers. Cancers. 2021;13:2872.

Zou LJ, Xiang QP, Xue XQ, Zhang C, Li CC, Wang C, et al. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer. Acta Pharm Sin. 2019;40:1436–47.

Article  CAS  Google Scholar 

Heemers HV, Debes JD, Tindall DJ. The role of the transcriptional coactivator p300 in prostate cancer progression. Adv Exp Med Biol. 2008;617:535–40.

Article  PubMed  PubMed Central